tbuckley/cabot-search huggingface dataset:
Genetic Landscape of Patients With Dilated Cardiomyopathy and a Systemic Immune-Mediated Disease
Authors: Sophie L V M Stroeks, Michiel T H M Henkens, Fernando Dominguez, Marco Merlo, Debby M E I Hellebrekers, Esther Gonzalez-Lopez, Matteo Dal Ferro, Juan Pablo Ochoa, Francesco Venturelli, Godelieve R F Claes, Max F G H M Venner, Ingrid P C Krapels, Els K Vanhoutte, Pieter van Paassen, Arthur van den Wijngaard, Maurits A Sikking, Rick van Leeuwen, Myrurgia Abdul Hamid, Xiaofei Li, Han G Brunner, Gianfranco Sinagra, Pablo Garcia-Pavia, Stephane R B Heymans, Job A J Verdonschot
Journal: JACC Heart Failure (2024)
Two distinct epithelial-to-mesenchymal transition programs control invasion and inflammation in segregated tumor cell populations
Authors: Khalil Kass Youssef, Nitin Narwade, Aida Arcas, Angel Marquez-Galera, Raúl Jiménez-Castaño, Cristina Lopez-Blau, Hassan Fazilaty, David García-Gutierrez, Amparo Cano, Joan Galcerán, Gema Moreno-Bueno, Jose P. Lopez-Atalaya, M. Angela Nieto
Journal: Nature Cancer (2024)

Epithelial-to-mesenchymal transition (EMT) triggers cell plasticity in embryonic development, adult injured tissues and cancer. Combining the analysis of EMT in cell lines, embryonic neural crest and mouse models of renal fibrosis and breast cancer, we find that there is not a cancer-specific EMT program. Instead, cancer cells dedifferentiate and bifurcate into two distinct and segregated cellular trajectories after activating either embryonic-like or adult-like EMTs to drive dissemination or inflammation, respectively. We show that SNAIL1 acts as a pioneer factor in both EMT trajectories, and PRRX1 drives the progression of the embryonic-like invasive trajectory. We also find that the two trajectories are plastic and interdependent, as the abrogation of the EMT invasive trajectory by deleting Prrx1 not only prevents metastasis but also enhances inflammation, increasing the recruitment of antitumor macrophages. Our data unveil an additional role for EMT in orchestrating intratumor heterogeneity, driving the distribution of functions associated with either inflammation or metastatic dissemination. Youssef et al. study epithelial-to-mesenchymal transition (EMT) programs in breast cancer and identify two interdependent trajectories coexisting within tumors, with EMT transcription factors such as PRRX1 at their nexus.
Rastermap: a discovery method for neural population recordings
Authors: Carsen Stringer, Lin Zhong, Atika Syeda, Fengtong Du, Maria Kesa, Marius Pachitariu
Journal: Nature Neuroscience (2024)

Abstract Neurophysiology has long progressed through exploratory experiments and chance discoveries. Anecdotes abound of researchers listening to spikes in real time and noticing patterns of activity related to ongoing stimuli or behaviors. With the advent of large-scale recordings, such close observation of data has become difficult. To find patterns in large-scale neural data, we developed ‘Rastermap’, a visualization method that displays neurons as a raster plot after sorting them along a one-dimensional axis based on their activity patterns. We benchmarked Rastermap on realistic simulations and then used it to explore recordings of tens of thousands of neurons from mouse cortex during spontaneous, stimulus-evoked and task-evoked epochs. We also applied Rastermap to whole-brain zebrafish recordings; to wide-field imaging data; to electrophysiological recordings in rat hippocampus, monkey frontal cortex and various cortical and subcortical regions in mice; and to artificial neural networks. Finally, we illustrate high-dimensional scenarios where Rastermap and similar algorithms cannot be used effectively.
Integrating brainstem and cortical functional architectures
Authors: Justine Y. Hansen, Simone Cauzzo, Kavita Singh, María Guadalupe García-Gomar, James M. Shine, Marta Bianciardi, Bratislav Misic
Journal: Nature Neuroscience (2024)

Abstract The brainstem is a fundamental component of the central nervous system, yet it is typically excluded from in vivo human brain mapping efforts, precluding a complete understanding of how the brainstem influences cortical function. In this study, we used high-resolution 7-Tesla functional magnetic resonance imaging to derive a functional connectome encompassing cortex and 58 brainstem nuclei spanning the midbrain, pons and medulla. We identified a compact set of integrative hubs in the brainstem with widespread connectivity with cerebral cortex. Patterns of connectivity between brainstem and cerebral cortex manifest as neurophysiological oscillatory rhythms, patterns of cognitive functional specialization and the unimodal–transmodal functional hierarchy. This persistent alignment between cortical functional topographies and brainstem nuclei is shaped by the spatial arrangement of multiple neurotransmitter receptors and transporters. We replicated all findings using 3-Tesla data from the same participants. Collectively, this work demonstrates that multiple organizational features of cortical activity can be traced back to the brainstem.
Advanced biomaterials for regenerative medicine and their possible therapeutic significance in treating COVID-19: a critical overview
Authors: Ashish K. Sarangi, Mohamed A. Salem, Mustafa D. Younus, Hala El-Haroun, Ahmed Mahal, Lizaranee Tripathy, Rajashree Mishra, Muhammed Shabil, Fahad A. Alhumaydhi, Mahalaqua Nazli Khatib, Ganesh Bushi, Sarvesh Rustagi, Debankur Dey, Prakasini Satapathy, Suhas Ballal, Pooja Bansal, Kiran Bhopte, Balvir S. Tomar, Snehasish Mishra, Mohammed Alissa, Ranjan K. Mohapatra, Zeinhom M. El-Bahy
Journal: International Journal of Surgery (2024)

The potential of biomaterials in medical sciences has attracted much interest, especially in promoting tissue regeneration and controlling immune responses. As COVID-19 pandemic broke out, there was an increased interest in understanding more about how biomaterials could be employed to fight this dreaded disease, especially in the context of regenerative medicine. Out of the numerous regenerative medicine possibilities, stem cells and scaffolding (grafting) technology are two major areas in modern medicines and surgery. Mesenchymal stem cells are useful in tissue repair, tailored therapy and treating COVID-19. Using biomaterials in COVID-19 treatment is intricate that needs multi- and cross-disciplinary research. Cell-based therapy and organ transplant pose immunological rejection challenge. Immunomodulation enhanced, tumorigenicity decreased, inflammation addressed and tissue damage restricted bioengineered stem cells need clinical insights and validation. Advanced stem cell based therapies should ideally be effective, safe and scalable. Cost and scalability shall dictate the dawn of technoeconomically feasible regenerative medicine. A globally standard and uniform approval process could accelerate translational regenerative medicine. Researchers, patient advocacy organisations, the regulators and the biopharmaceutical stakeholders need to join hands for easy navigation of regulatory measures and expeditious market entry of regenerative medicine. This article summarises advances in biomaterials for regenerative medicine, and their possible therapeutic benefits in managing infectious diseases like COVID-19. It highlights the significant recent developments in biomaterial design, scaffold construction, and stem cell-based therapies to treat tissue damage and COVID-19 linked immunological disregulation. It also highlights the potential contribution of biomaterials towards creating novel treatment strategies to manage COVID-19.
Knowledge abstraction and filtering based federated learning over heterogeneous data views in healthcare
Authors: Anshul Thakur, Soheila Molaei, Pafue Christy Nganjimi, Fenglin Liu, Andrew Soltan, Patrick Schwab, Kim Branson, David A. Clifton
Journal: npj Digital Medicine (2024)

Abstract Robust data privacy regulations hinder the exchange of healthcare data among institutions, crucial for global insights and developing generalised clinical models. Federated learning (FL) is ideal for training global models using datasets from different institutions without compromising privacy. However, disparities in electronic healthcare records (EHRs) lead to inconsistencies in ML-ready data views, making FL challenging without extensive preprocessing and information loss. These differences arise from variations in services, care standards, and record-keeping practices. This paper addresses data view heterogeneity by introducing a knowledge abstraction and filtering-based FL framework that allows FL over heterogeneous data views without manual alignment or information loss. The knowledge abstraction and filtering mechanism maps raw input representations to a unified, semantically rich shared space for effective global model training. Experiments on three healthcare datasets demonstrate the framework’s effectiveness in overcoming data view heterogeneity and facilitating information sharing in a federated setup.
Recent advances in HPV biotechnology: Understanding host-virus interactions and cancer progression-a review
Authors: Saba Yousaf, Anum Shehzadi, Muhammad Ahmad, Ahmad Asrar, Ishtiaq Ahmed, Hafiz M.N. Iqbal, Mohammed Hussen Bule
Journal: International Journal of Surgery (2024)

Cervical cancer ranks as the fourth most common cancer among women globally, posing a significant mortality risk. Persistent infection with high-risk human papillomavirus (HPV) is the primary instigator of cervical cancer development, often alongside co-infection with other viruses, precipitating various malignancies. This study aimed to explore recent biotechnological advances in understanding HPV infection dynamics, host interactions, and its role in oncogenesis. The gathered data shed light on HPV biology, host-virus interplay, viral co-infections, and cellular transformations leading to HPV-associated cancers. Recent years have seen the introduction of diverse vaccination strategies, including live attenuated, subunit, and DNA-based vaccines, complemented by innovative nanotechnology and plant-based products. Despite rich data addressing research inquiries, urgent calls echo for the implementation of contemporary screening and therapeutic modalities at clinical levels. Moreover, extensive public awareness campaigns are imperative to alleviate the burden of HPV-related diseases, emphasizing the necessity for proactive intervention strategies in combating this global health challenge.
An immune signature of postoperative cognitive decline: A prospective cohort study
Authors: Franck Verdonk, Amélie Cambriel, Julien Hedou, Ed Ganio, Grégoire Bellan, Dyani Gaudilliere, Jakob Einhaus, Maximilian Sabayev, Ina A. Stelzer, Dorien Feyaerts, Adam T. Bonham, Kazuo Ando, Benjamin Choisy, David Drover, Boris Heifets, Fabrice Chretien, Nima Aghaeepour, Martin S. Angst, Serge Molliex, Tarek Sharshar, Raphael Gaillard, Brice Gaudilliere
Journal: International Journal of Surgery (2024)

Background: Postoperative cognitive decline (POCD) is the predominant complication affecting patients over 60 years old following major surgery, yet its prediction and prevention remain challenging. Understanding the biological processes underlying the pathogenesis of POCD is essential for identifying mechanistic biomarkers to advance diagnostics and therapeutics. This study aimed to provide a comprehensive analysis of immune cell trajectories differentiating patients with and without POCD and to derive a predictive score enabling the identification of high-risk patients during the preoperative period. Material and Methods: Twenty-six patients aged 60 years old and older undergoing elective major orthopedic surgery were enrolled in a prospective longitudinal study, and the occurrence of POCD was assessed seven days after surgery. Serial samples collected before surgery, and one, seven, and 90 days after surgery were analyzed using a combined single-cell mass cytometry and plasma proteomic approach. Unsupervised clustering of the high-dimensional mass cytometry data was employed to characterize time-dependent trajectories of all major innate and adaptive immune cell frequencies and signaling responses. Sparse machine learning coupled with data-driven feature selection was applied to the pre-surgery immunological dataset to classify patients at risk for POCD. Results: The analysis identified cell-type and signaling-specific immune trajectories differentiating patients with and without POCD. The most prominent trajectory features revealed early exacerbation of JAK/STAT and dampening of inhibitory κB and nuclear factor-κB immune signaling responses in patients with POCD. Further analyses integrating immunological and clinical data collected before surgery identified a preoperative predictive model comprising one plasma protein and ten immune cell features that classified patients at risk for POCD with excellent accuracy (AUC=0.80, P =2.21e-02 U-test). Conclusion: Immune system-wide monitoring of patients over 60 years old undergoing surgery unveiled a peripheral immune signature of POCD. A predictive model built on immunological data collected before surgery demonstrated greater accuracy in predicting POCD compared to known clinical preoperative risk factors, offering a concise list of biomarker candidates to personalize perioperative management.
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
Authors: Xiaohua Wu, Yang Sun, Hongying Yang, Jing Wang, Hanmei Lou, Dan Li, Ke Wang, Hui Zhang, Tao Wu, Yuzhi Li, Chunyan Wang, Guiling Li, Yifeng Wang, Dapeng Li, Ying Tang, Mei Pan, Hongyi Cai, Weihu Wang, Bing Yang, Hua Qian, Qiuhong Tian, Desheng Yao, Ying Cheng, Bing Wei, Xiumin Li, Tao Wang, Min Hao, Xiaohong Wang, Tiejun Wang, Juntao Ran, Hong Zhu, Lijing Zhu, Xianling Liu, Yunxia Li, Lihong Chen, Qingshan Li, Xiaojian Yan, Fei Wang, Hongbing Cai, Yunyan Zhang, Zhiqing Liang, Funan Liu, Yi Huang, Bairong Xia, Pengpeng Qu, Genhai Zhu, Youguo Chen, Kun Song, Meili Sun, Zhengzheng Chen, Qiang Zhou, Lina Hu, Guzhalinuer Abulizi, Hongyan Guo, Sihai Liao, Yijing Ye, Ping Yan, Qiu Tang, Guoping Sun, Ting Liu, Dongmei Lu, Mingxiu Hu, Zhongmin M Wang, Baiyong Li, Michelle Xia
Journal: The Lancet (2024)
EP.06G.20 Advanced Squamous Cell Lung Carcinoma in Never Smokers: A Different Entity? Analysis from the Thoracic Tumor Registry in Spain (RTT)
Authors: M. Blanco, A. Collazo-Lorduy, M. Cobo, V. Calvo, M. Martínez- Cutillas, A. Cantero, D. Rodríguez-Abreu, E. Carcereny, J. Bosch-Barrera, M.R. García Campelo, R. López Castro, R. Bernabé, E. del Barco, A.L. Ortega, A. Sánchez, F. Aparisi-Aparisi, S. Vázquez, M. Guirado, J. Casal, K. Medina, S. Cerezo, C. Camps, J.L. Gonzalez-Larriba, M.A. Sala, B. Massutí, M. Dómine, B. Losada, A. Royuela, M. Provencio
Journal: Journal of Thoracic Oncology (2024)
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study
Authors: M. Peroni, A. Leonetti, V. Agnetti, F. Pratticò, M. Manini, A. Acunzo, E. Rapacchi, G. Mazzaschi, F. Perrone, P. Bordi, S. Trapani, G.P. Bacchini, S. Buti, M. Tiseo
Journal: Journal of Thoracic Oncology (2024)
EP.16B.02 Lung Cancer Patients' Preferred Methods of Receiving Information from their Treatment Teams: Insights from a Global Patient Experience Survey
Authors: K. Clayton, M. Daniels, J. Fox, B. Gaspar, M. Hennink, J. Mayans, A. McNamara, L. Pretorius, M. Rigney, M. Dohr
Journal: Journal of Thoracic Oncology (2024)
EP.17A.01 The Cumulative Incidence of Brain Metastases in US Medicare Patients with ALK+ mNSCLC Treated with Second-generation ALK TKIs
Authors: L. Bazhenova, D. Abrahami, K. Ramaswamy, B. Li, M. Davis, A.J. Epstein, Z.A. Marcum, N. Rifi, J. Kelton, K. Duncan, D. Uprety
Journal: Journal of Thoracic Oncology (2024)
EP.17B.05 Impact of Race and Ethnicity on Financial Toxicity and Outcomes in Lung Cancer
Authors: A.A. Khosla, N. Batra, R. Singh, I. Deshmukh, A. Harisingani, M. Rubens, A. Saxena, V. Ramamoorthy, I. Jaiyesimi, A. Desai
Journal: Journal of Thoracic Oncology (2024)
EP.12H.08 SOHO-02: Phase III Trial of BAY 2927088 In Patients with Locally Advanced or Metastatic NSCLC with HER2-Activating Mutations
Authors: K. Goto, J.C. Brase, J. Xu, S.-F. Pu, M. Montague-Dale, L. Mongay Soler, A. Passaro
Journal: Journal of Thoracic Oncology (2024)
EP.17B.03 Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC)
Authors: J. Bachler, A. Wang, L. Poisson, E. Adjei Boakye, S. Tam, S. Gadgeel, B. Movsas, B. Potugari
Journal: Journal of Thoracic Oncology (2024)
Should recreational cannabis be legalised in the UK?
Authors: David Nutt, Lucy Stafford, Robin M Murray, Laura Stack
Journal: BMJ (2024)

Demonising cannabis has not reduced harms and has kept the drug from patients who might benefit from it, say <b>David Nutt</b> and <b>Lucy Stafford</b> in this 2024 Maudsley debate. But <b>Laura Stack</b> and <b>Robin Murray</b> argue that legalisation in other countries has opened people up to more harms and that scientific evidence is still accumulating
EP.12H.01 A Phase 2 Study to Assess BDTX-1535, An Oral EGFR Inhibitor, in Patients with Non-Small Cell Lung Cancer
Authors: J. Patel, A. Spira, J. Stevenson, H. Chen, C. Baik, S. Gordon, J.T. Henry, M. Ahluwalia, M. Barve, C. Huang, J. Edenfield, M. Johnson, S. Eathiraj, J. Hajdenberg, S. Yurasov, H. Yu
Journal: Journal of Thoracic Oncology (2024)
EP.12A.37 Erlotinib: A Beacon of Hope in EGFR TKI-Progressed Lung Cancer, A Real-World Experience from a Tertiary Care Cancer Centre in South India
Authors: P. Thamarai Selvan, A. Krishnamurthy, A. John, S.S. Singh, V. Ramshankar, V. Radhakrishnan
Journal: Journal of Thoracic Oncology (2024)
EP.12E.01 OBX02-011, a Novel Oral ALK and EGFR Dual-target Tyrosine Kinase Inhibitor for the Treatment of Advanced NSCLC Patients
Authors: S. Heo, S. Lee, T. Ha, M. Baek, M. Kim, K. Jung, S.-E. Kim
Journal: Journal of Thoracic Oncology (2024)
EP.17F.02 Three-Stage Evolution of Lung Cancer Multidisciplinary Team in China
Authors: Y.-C. Zhang, J.-T. Zhang, S. Dong, Q. Zhou, W.-Z. Zhong, B.-C. Yin, P.J. Cui, M. Li, G.-W. Che, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2024)
EP.11D.02 An Investigator-Initiated Phase II Study of Combination Treatment of Nivolumab and TM5614, A PAI-1 Inhibitor for Previously Treated NSCLC
Authors: T. Masuda, T. Hirata, T. Sakamoto, Y. Tsubata, E. Ichihara, T. Kozuki, H. Shoda, E. Fukagawa, T. Yoshida, M. Fukutani, K. Tsuji-Takayama, Y. Orihashi, N. Hattori
Journal: Journal of Thoracic Oncology (2024)
P3.13E.02 Adjuvant Chemotherapy in cT1N0M0 Large-Cell Neuroendocrine Cancer with or without Pathological Upstaging
Authors: Y. Suzuki, I.S. Sarkaria, I.G. Christie, S.N. Mazur, S. Kim, A. Pennathur, J.D. Luketich, R. Landreneau, M.J. Schuchert
Journal: Journal of Thoracic Oncology (2024)
EP.17E.03 Using Healthcare Claims to Predict Costs by Stage for Medicare and Commercially Insured Patients with Non-Small Cell Lung Cancer
Authors: R. Smith, X. Cao, G. Cuyun Carter, I. Fayyaz, A. Pope, P. Ellenberg, X. Zhang, A. Fan, P. Limburg, T.M. Beer, B. Pyenson
Journal: Journal of Thoracic Oncology (2024)
EP.12A.30 Landscape of EGFR Mutations and Real-World Experience of Therapeutic Interventions - A Community Oncology Study
Authors: K. Jobanputra, V. Maniar, U. Maheshwari, D. Morzaria, A. Joshi, P. Kalaskar, K. Joshi, M. Randive, M. Mekha, N. Bayas, P. Kendre, S. Dhande, A. Shivchhand, C. Pethe, D. Pal, K. Chaudhari
Journal: Journal of Thoracic Oncology (2024)
EP.14B.01 Prognostic Impact of Tumour Size in Resected Thymic Epithelial Tumours - A Validation Analysis of the 9th TNM Staging System -
Authors: M. Abe, T. Karashima, Y. Abe, K. Ota, T. Sato, D. Noda, S. Takamori, Y. Takumi, A. Osoegawa, K. Sugio
Journal: Journal of Thoracic Oncology (2024)
EP.12A.09 Oligoprogression and Osimertinib Continuation Post-progression in Patients with EGFR-Mutations
Authors: V. Mai, J. Lee, L. Zhan, M.C. Brown, K. Balaratnam, K. Khan, S. Cheng, S. Barghout, F. Al-Agha, R. Raptis, K. Kuang, L. Eng, A.G. Sacher, P.A. Bradbury, N.B. Leighl, M. Cabanero, R. Hsu, P. Pal, M.S. Tsao, F.A. Shepherd, W. Xu, G. Liu
Journal: Journal of Thoracic Oncology (2024)
EP.12A.46 Age, Health Utility Scores (HUS), and Survival Outcomes in EGFR-Mutated Lung Cancer Patients Receiving 1L TKI Treatment
Authors: E. Faour, L. Everest, L. van Esveld, L. Zhan, M.C. Brown, K. Balaratnam, K. Khan, A. Ashkary, J. Reibel, E. Tsang, S. Barghout, F. Al-Agha, R. Raptis, K. Kuang, L. Eng, A. Sacher, P. Bradbury, N.B. Leighl, M. Tsao, F.A. Shepherd, W. Xu, S.M. Alibhai, G. Liu
Journal: Journal of Thoracic Oncology (2024)
EP.12A.18 Afatinib vs. Osimertinib as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations
Authors: T.T.A. Hoang, T.T.T. Nguyen, C.T.M. Pham, H.Q. Dong, K.T. Nguyen
Journal: Journal of Thoracic Oncology (2024)
EP.12B.12 Intrinsic ALK-TKI Resistance Due to Met-Coamplification in ALK+ NSCLC, Effectively Treated by Alectinib-crizotinib Combination
Authors: E.M. Urbanska, L.C. Melchior, J.B. Sørensen, E. Santoni-Rugiu
Journal: Journal of Thoracic Oncology (2024)
EP.11E.05 Outpatient Treatment Strategies for Grade 3-4 Immune-Mediated Hepatitis in Patients with Lung Cancer
Authors: A. Cardeña-Gutiérrez, P. Rodríguez-Hernáez, I.A. Castellano-Carneiro, A. Rosa-Díaz, C. Dorta-Pérez, M. Gutiérrez-Gordo, A. Herrero-Márquez, A. Arencibia, K. Medina-Sánchez
Journal: Journal of Thoracic Oncology (2024)
EP.13B.01 Selection of Optimal Therapy for Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Authors: W. Zhang, W. Zhao, Z. Guo, L. Ye, Z. Chen, H. Wang, L. Zhao, K. Xu, X. Liu, Y. Liu, Y. He
Journal: Journal of Thoracic Oncology (2024)
EP.11A.13 Efficacy and Safety of Immune-Checkpoint Inhibitors in Advanced NSCLC Patients with Rare Mutation after Developing Targeted Therapy Resistance
Authors: W. Zhang, Y. Li, H. Jiang, D. Wang, B. Liu, F. Qian, B. Zhang, Y. Zhang, R. Li, W. Ma, B. Han, Y. Lou
Journal: Journal of Thoracic Oncology (2024)
EP.13C.07 Long-Term Oncological Outcomes of Resected Bronchopulmonary Neuroendocrine Tumors
Authors: M.E. Cano, A.M. García Cardoso, J.J. Camargo, S.M. Camargo, J.C. Felicetti, A.C. Gonçalves Castelo, V.A. Livramento, F.A. Perin, S.A. Soder
Journal: Journal of Thoracic Oncology (2024)
EP.09B.03 Salvage Surgery Following Inductiontherapy for Advanced ALK-Positive NSCLC: Pathological Response and Surgical Outcomes
Authors: J-Y. Ding, C. Zhang, H-Z. Hong, Z-B. Qiu, Y-F. Qi, H-J. Li, Y-L. Wu, W-Z. Zhong
Journal: Journal of Thoracic Oncology (2024)
EP.08F.12 Toxicity and Outcomes by Radio-Sensitizing Chemotherapy Regimen for Unresectable Stage III NSCLC in British Columbia, Canada
Authors: M-F. Damours, M-H. Denault, J. Feng, S. Kuang, J. Laskin, B. Leung, S. Sun, B. Melosky, M. Liu, H. Carolan, C. Ho
Journal: Journal of Thoracic Oncology (2024)
EP.12A.34 Chemotherapy and/or Immunotherapy after Progression on Tyrosine Kinase Inhibitors in EGFR Mutant Non-Small Cell Lung Cancer Patients.
Authors: M. Okunrobo, D. Walker, K. Dumais, H. Powery, P. Izquierdo, L.E. Raez
Journal: Journal of Thoracic Oncology (2024)
EP.11A.01 Evaluation of Six Clinical Prognostic Scores in NSCLC Patients Undergoing First Line Chemoimmunotherapy
Authors: Y. Wang, J. Sun, L. Wang, L. Feng, Z. Fan, J. Han, X. Zhang, X. Zhou, D. Li, H. Jin, J. Liu, J. Zuo
Journal: Journal of Thoracic Oncology (2024)
EP.12C.04 Location of Metastases and Prognosis of Patients with Metastatic KRAS-Mutant Non-Small Cell Lung Cancer
Authors: L. Gutiérrez Sainz, I. Ozáez, O. Higuera Gómez, J. Villamayor, I. Esteban Rodríguez, R.M. Regojo Zapata, A. Peláez García, V. Heredia Soto, M. Mendiola, R. Rosas Alonso, C. Rodríguez Antolín, I. Ibáñez de Cáceres, J. de Castro Carpeño
Journal: Journal of Thoracic Oncology (2024)
EP.13A.01 Preliminary Efficacy and Safety of Adebrelimab Plus Famitinib as Later-line Treatment for Extensive-Stage Small Cell Lung Cancer: A Phase 2 Trial
Authors: T. Chen, M. Wang, Y. Chen, Y. Cao, X. Hu, L. Tian, C. Zhao, Y. Liu
Journal: Journal of Thoracic Oncology (2024)